Integrated Report

Overview

The report describes the Mochida Pharmaceutical Group's FY2022 performance and strategy across its pharmaceutical, biomaterials and healthcare businesses. It identifies five material issues and reports that targets and initiatives were established for them. Environmental highlights include a 46% carbon-emissions reduction target by FY2030 and carbon neutrality by 2050. The Group also began TCFD-aligned climate governance and disclosure after declaring support for the TCFD Recommendations in June 2023.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 April 2022 – 31 March 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services